1,720,968 research outputs found
Leber miliary aneurysms and multiple sclerosis
No full textPURPOSE. To describe a patient with Leber miliary aneurysms who fulfilled the criteria for clinically definite multiple sclerosis (MS) in remission. METHODS. Case report. RESULTS. We performed a complete ophthalmologic examination in a 45-year-old woman who was referred to our department for retinal vascular abnormalities in her left eye. Twenty-eight years previously, the patient had been diagnosed with MS. Following a complete ophthalmologic examination, the patient was diagnosed with Leber miliary aneurysms and coincident MS in remission. To our knowledge, there are no previous reports describing association between Leber miliary aneurysms and MS. CONCLUSIONS. Leber miliary aneurysms have been found in association with multiple ocular and systemic syndromes. In this report, we suggest another possible systemic association (MS) with Leber miliary aneurysms (Eur J Ophthalmol 2009; 19: 690-3
Foveal geographic atrophy following intravitreal pegaptanib sodium (Macugen) for drusenoid pigment epithelium detachment.
No full text
Trou maculaire lamellaire après injection intravitréenne de pegaptanib sodium pour œdème maculaire diabétique
No full textIntroduction
The benefit of immediate focal photocoagulation for diabetic macular edema was demonstrated in the Early Treatment Diabetic Retinopathy Study (ETDRS). Anti-vascular endothelial growth factor (VEGF) therapy have been focused as alternative or adjunct treatments. We report a case of a patient who developed lamellar macular hole, one month after intravitreal pegaptanib sodium injection for diabetic macular edema.
Materials and Methods
Interventional case report.
Results
A 66 – year-old patient with type 2 diabetes presented in the right eye a cystoid diabetic macular edema, without clinically detectable vitreomacular traction. One injection of pegaptanib 0.05ml/0.3mg was administered without complication. One month after intravitreal pegaptanib sodium injection (0.05ml/0.3mg), the patient presented no visual acuity improvement and complained of newly developed metamorphopsia. Fundus biomicroscopy and OCT revealed deep reduction of the cystoid macular edema, with lamellar macular hole formation, characterized by visibly detached posterior hyaloid, roof of the cyst above the macula, and foveal photoreceptors layer intact below the area of foveal dehiscence.
Discussion
Despite a lamellar hole could result from the degenerative process associated with cystoid macular edema, the pathogenesis of lamellar macular hole can be attributed in our case to the intravitreal injection, which may have induced vitreous incarceration, causing a vitreoretinal traction at the macula and the development of a lamellar macular hole. Alternatively or in association, pegaptanib itself may have caused the lamellar macular hole by inducing a sudden reduction of the diabetic macular edema and hence, the exacerbation of tangential traction of the posterior vitreous on the overlying macular retina. On the other hand, in our patient, we were not able to detect any other potential causes, such as epiretinal membrane formation and/or contraction, after the intravitreal pegaptanib injection.
Conclusion
Lamellar macular hole seems to be a potential complication of pegaptanib injection, even in patients without pre treatment clinically detectable vitreo-macular traction
Local resection versus combined local resection and plaque radiotherapy in the treatment of choroidal melanoma.
No full text
Intravitreal pegaptanib sodium (Macugen((R))) for diabetic macular oedema
No full textPurpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen((R))) in patients with diabetic macular oedema (DMO). Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow-up visit. Results: Sixty-three eyes of 48 patients with a minimum of 6 months of follow-up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p < 0.001) as soon as the 6-week follow-up. Most eyes (60/63) required a mean of 3.03 +/- 0.9 repeated treatments, over a mean follow-up period of 6.7 +/- 1.2 months, to achieve significant improvements in mean BCVA (p < 0.001) and mean CMT (p < 0.001). In our series, the lower visual acuities tended to congregate in the group with the less-defined PR band (p < 0.001) and the lower CMT tended to congregate in the group with the best-defined PR band (p = 0.04), even though the higher CMT did not tend to congregate in the group with the less-defined PR band. Conclusion: Our findings demonstrate that selective inhibition by intravitreal pegaptanib sodium of vascular endothelial growth factor (VEGF)-165 may produce a clinically meaningful and statistically significant benefit in the treatment of DMO
High-Definition Optical Coherence Tomographic Visualization of Photoreceptor Layer and Retinal Flecks in Fundus Albipunctatus Associated With Cone Dystrophy
No full textShort-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection.
No full textPegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
No full textPurpose. To report the outcomes after primary intravitreal pegaptanib sodium in patients with diabetic macular edema (DME). Methods. We conduced a retrospective analysis of eyes with DME treated with primary intravitreal pegaptanib sodium (Macugen) (intravitreal pegaptanib group). The results were compared with the ones of eyes treated with intravitreal pegaptanib sodium associated with macular laser photocoagulation (combined treatment group), and the ones of eyes treated with primary macular laser photocoagulation (macular laser photocoagulation group). Results. For the intravitreal pegaptanib group (13 eyes), we found significant changes in mean best-corrected visual acuity (BCVA) and reductions in mean central macular thickness (CMT) at the last follow-up visit (P = .0014 and P = .0001). For the macular laser photocoagulation group (15 eyes), we found no statistically significant changes in mean BCVA and CMT at the last follow-up visit (P > .05). For the combined treatment group (12 eyes), we found no significant changes in mean BCVA at the last follow-up visit (P > .05) despite significant reductions in mean CMT (P = .0188). Conclusion. Intravitreal pegaptanib treatment alone may be superior to macular laser photocoagulation alone and to combined intravitreal pegaptanib treatment associated with macular laser photocoagulation in patients with DME. Copyright (C) 2009 G. Querques et al
- …
